Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.

Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA.

Genes Dev. 2011 Dec 1;25(23):2465-79. doi: 10.1101/gad.180331.111.

2.

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.

Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, Glück S.

Breast Cancer Res Treat. 2012 Feb;132(1):215-23. doi: 10.1007/s10549-011-1889-0. Epub 2011 Dec 3.

3.

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM.

Cancer Discov. 2011 Jun;1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028. Epub 2011 Jun 1.

4.

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.

Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, Mohri D, Miyabayashi K, Asaoka Y, Maeda S, Ikenoue T, Tateishi K, Wright CV, Koike K, Omata M, Moses HL.

J Clin Invest. 2011 Oct;121(10):4106-17. doi: 10.1172/JCI42754. Epub 2011 Sep 19.

5.

Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids.

Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJ, van Amersfoort M, Vermaat JS, Moerer P, Ishihara K, Kalkhoven E, Beijnen JH, Derksen PW, Medema RH, Martens AC, Brenkman AB, Voest EE.

Cancer Cell. 2011 Sep 13;20(3):370-83. doi: 10.1016/j.ccr.2011.08.010.

6.

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.

Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M.

Nature. 2011 Feb 24;470(7335):548-53. doi: 10.1038/nature09707. Epub 2011 Feb 16.

7.

Mutant BRAF melanomas--dependence and resistance.

Poulikakos PI, Rosen N.

Cancer Cell. 2011 Jan 18;19(1):11-5. doi: 10.1016/j.ccr.2011.01.008. Review.

8.

S100A8/A9 activate key genes and pathways in colon tumor progression.

Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G.

Mol Cancer Res. 2011 Feb;9(2):133-48. doi: 10.1158/1541-7786.MCR-10-0394. Epub 2011 Jan 12. Erratum in: Mol Cancer Res. 2011 Sep;9(9):1266.

9.

DNA damage-mediated induction of a chemoresistant niche.

Gilbert LA, Hemann MT.

Cell. 2010 Oct 29;143(3):355-66. doi: 10.1016/j.cell.2010.09.043.

10.

The landscape of somatic copy-number alteration across human cancers.

Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M.

Nature. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822.

11.

Tumor self-seeding by circulating cancer cells.

Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massagué J.

Cell. 2009 Dec 24;139(7):1315-26. doi: 10.1016/j.cell.2009.11.025.

12.

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

Ebos JM, Lee CR, Kerbel RS.

Clin Cancer Res. 2009 Aug 15;15(16):5020-5. doi: 10.1158/1078-0432.CCR-09-0095. Epub 2009 Aug 11. Review.

13.

Latent bone metastasis in breast cancer tied to Src-dependent survival signals.

Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massagué J.

Cancer Cell. 2009 Jul 7;16(1):67-78. doi: 10.1016/j.ccr.2009.05.017.

14.

Genes that mediate breast cancer metastasis to the brain.

Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J.

Nature. 2009 Jun 18;459(7249):1005-9. doi: 10.1038/nature08021. Epub 2009 May 6.

15.

Therapeutic options for metastatic breast cancer.

Morris PG, McArthur HL, Hudis CA.

Expert Opin Pharmacother. 2009 Apr;10(6):967-81. doi: 10.1517/14656560902834961 . Review.

PMID:
19351274
16.

Myeloid-derived suppressor cells: linking inflammation and cancer.

Ostrand-Rosenberg S, Sinha P.

J Immunol. 2009 Apr 15;182(8):4499-506. doi: 10.4049/jimmunol.0802740. Review.

17.

Myeloid-derived suppressor cells as regulators of the immune system.

Gabrilovich DI, Nagaraj S.

Nat Rev Immunol. 2009 Mar;9(3):162-74. doi: 10.1038/nri2506. Review.

18.

MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer.

Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y.

Cancer Cell. 2009 Jan 6;15(1):9-20. doi: 10.1016/j.ccr.2008.11.013.

19.

Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.

Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J.

PLoS Biol. 2008 Dec 2;6(12):2853-68. doi: 10.1371/journal.pbio.0060301.

20.

CXCR2 antagonists for the treatment of pulmonary disease.

Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS.

Pharmacol Ther. 2009 Jan;121(1):55-68. doi: 10.1016/j.pharmthera.2008.10.005. Epub 2008 Oct 31. Review.

PMID:
19026683
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk